Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

ESO-ESMO 4rd International Consensus Guidelines for Breast Cancer in Young Women (BCY4).

Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA Jr, Bianchi-Micheli G, Cardoso MJ, Curigliano G, Gelmon KA, Harbeck N, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Spanic T, Stearns V, Wengström Y, Peccatori F, Pagani O.

Ann Oncol. 2020 Mar 18. pii: S0923-7534(20)36363-8. doi: 10.1016/j.annonc.2020.03.284. [Epub ahead of print]

PMID:
32199930
2.

Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M.

J Clin Oncol. 2020 Mar 13:JCO1901902. doi: 10.1200/JCO.19.01902. [Epub ahead of print]

PMID:
32167862
3.

Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.

Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F.

Cancers (Basel). 2020 Mar 6;12(3). pii: E617. doi: 10.3390/cancers12030617.

4.

Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial.

Galli G, Signorelli D, Vernieri C, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Gavazzi C, Rizzo AM, Corsetto P, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Ann Oncol. 2019 Apr;30 Suppl 2:ii68. doi: 10.1093/annonc/mdz063.086. No abstract available.

5.

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice.

Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group.

J Pathol. 2020 Mar 4. doi: 10.1002/path.5406. [Epub ahead of print] Review.

PMID:
32129476
6.

Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast.

Di Cosimo S, Appierto V, Silvestri M, Ortolan E, De Cecco L, Veneroni S, Pruneri G, Vingiani A, Belfiore A, Scaperrotta G, Folli S, Daidone MG.

Ann Oncol. 2020 Mar;31(3):435-437. doi: 10.1016/j.annonc.2019.11.022. Epub 2019 Dec 11. No abstract available.

PMID:
32067686
7.

Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.

Lazzeroni M, DeCensi A, Guerrieri-Gonzaga A, Pagan E, Bagnardi V, Macis D, Serrano D, Vingiani A, Bonizzi G, Barberis M, Pruneri G, Wagner S, Gandini S, Viale G, Bonanni B.

Mod Pathol. 2020 Jan 10. doi: 10.1038/s41379-020-0452-0. [Epub ahead of print]

PMID:
31925342
8.

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma.

Minna E, Brich S, Todoerti K, Pilotti S, Collini P, Bonaldi E, Romeo P, Cecco L, Dugo M, Perrone F, Busico A, Vingiani A, Bersani I, Anichini A, Mortarini R, Neri A, Pruneri G, Greco A, Borrello MG.

Cancers (Basel). 2020 Jan 1;12(1). pii: E112. doi: 10.3390/cancers12010112.

9.

Gastroblastoma in Adulthood-A Rarity among Rare Cancers-A Case Report and Review of the Literature.

Centonze G, Mangogna A, Salviato T, Belmonte B, Cattaneo L, Monica MAT, Garzone G, Brambilla C, Pellegrinelli A, Melotti F, Testi A, Monti V, Kankava K, Gasparini P, Dagrada G, Mazzaferro V, Cotsoglou C, Collini P, Pruneri G, Milione M.

Case Rep Pathol. 2019 Nov 28;2019:4084196. doi: 10.1155/2019/4084196. eCollection 2019.

10.

Anticancer innovative therapy: Highlights from the ninth annual meeting.

Volpari T, De Santis F, Bracken AP, Pupa SM, Buschbeck M, Wegner A, Di Cosimo S, Lisanti MP, Dotti G, Massaia M, Pruneri G, Anichini A, Fortunato O, De Braud F, Del Vecchio M, Di Nicola M.

Cytokine Growth Factor Rev. 2020 Feb;51:1-9. doi: 10.1016/j.cytogfr.2019.12.002. Epub 2019 Dec 13. Review.

PMID:
31862236
11.

WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells.

Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, Criscitiello C, Lovati G, Meliksetyan M, Carugo A, Curigliano G, Natoli G, Pelicci PG, Lanfrancone L.

Breast Cancer Res. 2019 Nov 21;21(1):123. doi: 10.1186/s13058-019-1216-y.

12.

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.

Di Cosimo S, Appierto V, Silvestri M, Pruneri G, Vingiani A, Perrone F, Busico A, Folli S, Scaperrotta G, de Braud FG, Bianchi GV, Cavalieri S, Daidone MG, Dugo M.

Cancers (Basel). 2019 Nov 8;11(11). pii: E1753. doi: 10.3390/cancers11111753.

13.

Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms (H-NENs): histology and molecular analysis, two sides of the same coin.

Busico A, Maisonneuve P, Prinzi N, Pusceddu S, Centonze G, Garzone G, Pelligrinelli A, Giacomelli L, Mangogna A, Paolino C, Belfiore A, Kankava K, Perrone F, Tamborini E, Pruneri G, Fazio N, Milione M.

Neuroendocrinology. 2019 Sep 27. doi: 10.1159/000503722. [Epub ahead of print]

PMID:
31557757
14.

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy.

Hong SP, Chan TE, Lombardo Y, Corleone G, Rotmensz N, Bravaccini S, Rocca A, Pruneri G, McEwen KR, Coombes RC, Barozzi I, Magnani L.

Nat Commun. 2019 Sep 2;10(1):3840. doi: 10.1038/s41467-019-11721-9.

15.

Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer.

Perone Y, Farrugia AJ, Rodríguez-Meira A, Győrffy B, Ion C, Uggetti A, Chronopoulos A, Marrazzo P, Faronato M, Shousha S, Davies C, Steel JH, Patel N, Del Rio Hernandez A, Coombes C, Pruneri G, Lim A, Calvo F, Magnani L.

Nat Commun. 2019 Aug 19;10(1):3791. doi: 10.1038/s41467-019-11801-w.

16.

Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.

De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, De Braud F, Apolone G, Sant M, Di Cosimo S.

Clin Transl Oncol. 2019 Aug 1. doi: 10.1007/s12094-019-02188-7. [Epub ahead of print]

PMID:
31372896
17.

Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.

Punzi S, Meliksetian M, Riva L, Marocchi F, Pruneri G, Criscitiello C, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, Curigliano G, Pelicci PG, Lanfrancone L.

Cells. 2019 Jun 18;8(6). pii: E605. doi: 10.3390/cells8060605.

18.

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.

Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A.

J Pathol Clin Res. 2019 Oct;5(4):217-226. doi: 10.1002/cjp2.135. Epub 2019 Jul 9.

19.

SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer.

Perone Y, Farrugia AJ, Rodríguez-Meira A, Győrffy B, Ion C, Uggetti A, Chronopoulos A, Marrazzo P, Faronato M, Shousha S, Davies C, Steel JH, Patel N, Del Rio Hernandez A, Coombes C, Pruneri G, Lim A, Calvo F, Magnani L.

Nat Commun. 2019 May 9;10(1):2115. doi: 10.1038/s41467-019-09676-y. Erratum in: Nat Commun. 2019 Aug 19;10(1):3791.

20.

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment.

Carbone A, Gloghini A, Pruneri G, Dolcetti R.

Cancer Med. 2019 Jun;8(6):3012-3016. doi: 10.1002/cam4.2168. Epub 2019 May 8. Review.

21.

Identification of potentially druggable molecular alterations in skin adnexal malignancies.

Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, Licitra L, Pruneri G, Bossi P, Perrone F.

J Dermatol. 2019 Jun;46(6):507-514. doi: 10.1111/1346-8138.14889. Epub 2019 Apr 30.

PMID:
31038235
22.

The landscape of d16HER2 splice variant expression across HER2-positive cancers.

Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L.

Sci Rep. 2019 Mar 5;9(1):3545. doi: 10.1038/s41598-019-40310-5.

23.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, Carniti C, Heavican TB, Pellegrinelli A, Pruneri G, Butler A, Bhosle SG, Chiappella A, Di Rocco A, Zinzani PL, Zaja F, Piva R, Inghirami G, Wang W, Palomero T, Iqbal J, Neri A, Campbell PJ, Corradini P.

Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.

24.

ESR1 mutations in metastatic lobular breast cancer patients.

Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C.

NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019.

25.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.

Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F.

Sci Rep. 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.

26.

Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs.

Dell'Omo G, Crescenti D, Vantaggiato C, Parravicini C, Borroni AP, Rizzi N, Garofalo M, Pinto A, Recordati C, Scanziani E, Bassi FD, Pruneri G, Conti P, Eberini I, Maggi A, Ciana P.

Br J Cancer. 2019 Mar;120(5):537-546. doi: 10.1038/s41416-018-0372-7. Epub 2019 Feb 11.

27.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S.

J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.

28.

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.

Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio MC, Matteucci P, Carniti C, Facchetti F, Rossi G, Corradini P.

Leukemia. 2019 Apr;33(4):1047-1051. doi: 10.1038/s41375-018-0320-9. Epub 2019 Jan 10. No abstract available.

29.

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Clin Lung Cancer. 2019 May;20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011. Epub 2018 Dec 19.

PMID:
30617039
30.

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).

Vernieri C, Pusceddu S, Fucà G, Indelicato P, Centonze G, Castagnoli L, Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, Pruneri G, Milione M, de Braud F.

Int J Cancer. 2019 Apr 1;144(7):1704-1712. doi: 10.1002/ijc.32042. Epub 2019 Jan 7.

31.

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.

Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S.

Cancer Treat Rev. 2019 Jan;72:45-55. doi: 10.1016/j.ctrv.2018.11.001. Epub 2018 Nov 10. Review.

PMID:
30476750
32.

Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.

Cetti E, Di Marco T, Mauro G, Mazzoni M, Lecis D, Minna E, Gioiosa L, Brich S, Pagliardini S, Borrello MG, Pruneri G, Anania MC, Greco A.

Cancer Lett. 2019 Feb 1;442:362-372. doi: 10.1016/j.canlet.2018.11.010. Epub 2018 Nov 14.

PMID:
30445205
33.

Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.

Milione M, Maisonneuve P, Pellegrinelli A, Spaggiari P, Centonze G, Coppa J, Delconte G, Droz Dit Busset M, Lanhazo O, Pruneri G, Mazzaferro V.

Eur J Surg Oncol. 2019 May;45(5):755-760. doi: 10.1016/j.ejso.2018.10.052. Epub 2018 Oct 11.

PMID:
30366875
34.

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).

Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators.

Cancer Treat Rev. 2018 Dec;71:76-87. doi: 10.1016/j.ctrv.2018.10.001. Epub 2018 Oct 5.

PMID:
30366202
35.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

36.

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart M, Rothé F, Sotiriou C.

NPJ Breast Cancer. 2018 Aug 6;4:23. doi: 10.1038/s41523-018-0077-3. eCollection 2018.

37.

RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.

Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V.

Oncogene. 2018 Dec;37(50):6463-6476. doi: 10.1038/s41388-018-0424-8. Epub 2018 Aug 3.

38.

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L.

Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23.

39.

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M, Marabese M, Broggini M, Marino M, Trama A, Rulli E, Hollander L, Pruneri G, Torri V, Garassino MC.

Clin Lung Cancer. 2018 Sep;19(5):e811-e814. doi: 10.1016/j.cllc.2018.06.005. Epub 2018 Jul 3.

PMID:
30033090
40.

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C; International Immuno-Oncology Biomarker Working Group.

Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157. doi: 10.1016/j.semcancer.2018.07.001. Epub 2018 Jul 7. Review.

PMID:
29990622
41.

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F.

Ann Oncol. 2018 Aug 1;29(8):1800-1806. doi: 10.1093/annonc/mdy197.

42.

Extensive and systematic rewiring of histone post-translational modifications in cancer model systems.

Noberini R, Osti D, Miccolo C, Richichi C, Lupia M, Corleone G, Hong SP, Colombo P, Pollo B, Fornasari L, Pruneri G, Magnani L, Cavallaro U, Chiocca S, Minucci S, Pelicci G, Bonaldi T.

Nucleic Acids Res. 2018 May 4;46(8):3817-3832. doi: 10.1093/nar/gky224.

43.

Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis.

Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P, Vanoli A, Tagliabue G, Pisa E, Messerini L, Centonze G, Inzani F, Scarpa A, Papotti M, Volante M, Sessa F, Fazio N, Pruneri G, Rindi G, Solcia E, La Rosa S, Capella C.

Endocr Relat Cancer. 2018 May;25(5):583-593. doi: 10.1530/ERC-17-0557. Epub 2018 Mar 28.

PMID:
29592868
44.

Immune Infiltration in Invasive Lobular Breast Cancer.

Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 Jul 1;110(7):768-776. doi: 10.1093/jnci/djx268.

45.

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.

Han SN, Amant F, Cardonick EH, Loibl S, Peccatori FA, Gheysens O, Sangalli CA, Nekljudova V, Steffensen KD, Mhallem Gziri M, Schröder CP, Lok CAR, Verest A, Neven P, Smeets A, Pruneri G, Cremonesi M, Gentilini O; International Network on Cancer, Infertility and Pregnancy.

Breast Cancer Res Treat. 2018 Apr;168(2):551-557. doi: 10.1007/s10549-017-4611-z. Epub 2017 Dec 12.

PMID:
29235045
46.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

47.

Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.

Criscitiello C, Bagnardi V, Pruneri G, Vingiani A, Esposito A, Rotmensz N, Curigliano G.

Eur J Cancer. 2017 Dec;87:164-171. doi: 10.1016/j.ejca.2017.10.011. Epub 2017 Nov 15.

PMID:
29154173
48.

A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.

Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F.

Ann Oncol. 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691.

49.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Review.

50.

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F.

Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17.

PMID:
28822332

Supplemental Content

Loading ...
Support Center